
The European Union won’t weaken merger rules during the COVID-19 pandemic even if companies announced that they are likely to go bust without a deal, a senior EU antitrust official said on Wednesday, November 18.
European Commission Director General for Competition Olivier Guersent said he expected more companies to use the “failing firm defence” to try to justify mergers during the crisis, reported Reuters. However, he said regulators didn’t see the need to relax the rules.
“Why should we? What’s the rationale for that? Which criteria should we relax?” Guersent told an American Chamber of Commerce EU online event.
“We will not get out of this crisis better if we weaken competition policy,” he said.
He also said the Commission planned to offer guidance soon to companies involved in large investments and in digital projects to allow them to cooperate with peers without running foul of EU antitrust rules against cartels or anti-competitive practices.
Guersent issued a so-called comfort letter to the pharmaceutical industry in April so drugmakers can coordinate to increase production and to improve the supply of urgently needed critical hospital medicines to treat COVID-19 patients.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas